NAKI Therapeutics is an innovative research-focused biopharmaceutical company. Our core technology is surrounding Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy with ground-breaking allogeneic or ‘off-the-shelf’ expansion technology and a ‘first-in-class’ solid tumor molecular target-CD147.
Our approach is to re-engineer NK cells-which belong to the human innate immune system to target the specific cancer cell surface marker CD147, and thereby kill the cancer cells more effectively and safely in comparison to existing treatments.
To deliver this therapy cost-effectively and in a scalable way, we also have developed proprietary methods to expand ‘memory-like’, highly potent, ‘off-the-shelf’ NK and CAR-NK cells fast and with high purity.
Our initial indication is hepatocellular carcinoma (HCC), a devastating solid tumor with marginally effective standard of care.
Our approach is to re-engineer NK cells-which belong to the human innate immune system to target the specific cancer cell surface marker CD147, and thereby kill the cancer cells more effectively and safely in comparison to existing treatments.
To deliver this therapy cost-effectively and in a scalable way, we also have developed proprietary methods to expand ‘memory-like’, highly potent, ‘off-the-shelf’ NK and CAR-NK cells fast and with high purity.
Our initial indication is hepatocellular carcinoma (HCC), a devastating solid tumor with marginally effective standard of care.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Combination therapy (anti-CD147 CAR-NK + IL15)
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
